Defiance ETFs introduces NVOX, a leveraged ETF offering 2X exposure to Novo Nordisk's stock price movements, targeting the ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

Lilly said patients taking Zepbound lost about 20% of their weight on average compared with nearly 14% for Wegovy. The drug ...

In the fierce race to dominate the weight loss drug market, global pharmaceutical giant Eli Lilly announced on Wednesday that ...

If you want to take Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist medication for weight management, you might also be exploring telemedicine and the convenience of getting a ...

For some, the issue with GLP-1 drugs like Ozempic and Mounjaro isn't getting access to these game-changing medications, but ...

Eli Lilly's Zepbound has outperformed Novo Nordisk's Wegovy in a pivotal clinical trial, marking a significant milestone in ...

Wegovy (semaglutide) is a prescription drug prescribed for weight loss and to reduce the risk of serious cardiovascular problems. It helps aid weight loss by acting like a hormone in your brain ...

Several obesity experts said perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications.

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...

A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight loss is most effective at helping people lose more weight in less time.